Reuben Ben-David: Gem/Doce induction + maintenance is superior to induction only
Vignesh Packiam, Associate Professor of Urologic Oncology at Rutgers Cancer Institute of New Jersey, shared a post by Reuben Ben-David, Society of Urological Oncology (SUO) fellow at the Mount Sinai Hospital NYC, on X/Twitter, adding:
”Nice paper Reuben Ben-David, John Sfakianos!! Important to learn optimal Gem/Doce protocol. Data like this on the implications of maintenance are valuable. Anecdotally I have found that 2g Gem in combo regimens has more topical issues.”
Quoting Reuben Ben-David’s post:
”Excited about our latest publication!
Gem/Doce induction + maintenance is superior to induction only. The use of 2 grams of gemcitabine improved all grades of recurrence but didn’t decrease high-grade recurrences over 1 gram of gemcitabine. Gem/Doce is gaining grounds in the treatment of NMIBC.”
Source: Vignesh Packiam/X and Reuben Ben-David/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023